



SmartVascular Dx



Patient Information		Specimen Information		Practitioner Information	
Name		Collection Date/Time	05/13/2025 09:40 PT	Name	Maximus, Paul
Age 69 Sex F		Received Date/Time	05/15/2025 10:00 PT	Client ID	3047 Paul Maximus
DOB		Report Date/Time	05/27/2025 17:39 PT	Address	903-750W. Broadway Vancouver, BC V5Z 1K1
Accession ID		Report Status	Final		

Patient Acute Coronary Syndrome (ACS) Profile is **Elevated**


SVDx Score: 22.69%



Graph

Theratio size and location for each biomarker bar located on the Protein Biomarker Graph indicates the relative impact in the formation and progression of cardiac lesions. The chart reads right to left. Red bars above zero line indicate factors that increase the probability of experiencing Acute Coronary Syndrome (ACS). Green bars below zero line indicate factors that decrease your probability of experiencing an ACS.

■ Decreased event ratio
■ Increased event ratio



Test Interpretation:

- 1 YourSMART Vascular Dx score indicates that **22.69%** (Absolute Risk) of individuals of your age, sex, and score had a cardiac event within a 5 year time period. Your expected score of **3.09%** is where you should be according to your current age and sex.
- 2 Your SMART Vascular Dx score indicates that you are **7.34** times (Relative Risk) more likely to experience an ACS (heart attack) than would be expected for your age and sex.
- 3 This SMART Vascular Dx score classifies you at **High-Risk** by AHA/ACC Cardiovascular Risk Guidelines.

SmartVascular Dx Test				SmartVascular Dx Expected Score Gap				
1	< 3.50%	3.50% - 7.49%	≥ 7.50%	1		2	< 5 Times	≥ 5 Times
SmartVascular Dx Score (Absolute Risk)			22.69	Expected Score for Age and Sex	3.09	Score Gap (Relative Risk)		7.34
3	AHA/ACC Guidelines Class			This patient is at high risk and should be treated as such. A low threshold for additional testing should be applied to this patient to better define the clinical picture and treatment plan. Aggressive lifestyle modification, supplements, and or medication should be considered. If the clinical situation warrants it, and the patient is not currently under the care of a cardiologist, referral to a cardiologist might be warranted.				
	High							

The SmartVascular Dx measures protein biomarkers of active Unstable Lesion formation and progression produced by the pathways (chemotaxis, apoptosis, cell proliferation, inflammation & angiogenesis). An integrated score calculated with established clinical risk factors demonstrates clinical utility that identifies the vulnerable patient and improves accuracy in cardiovascular risk classification, which could lead to improved preventive care and fewer deaths.

METHODOLOGY: Chemiluminescent Immunoassay

Morningstar Laboratories, a Smart Health Diagnostics Company, is authorized under the Clinical Laboratory Improvement Amendments (CLIA) to develop and perform laboratory testing. This test was developed, and Morningstar Laboratories determined its performance characteristics. The US Food and Drug Administration (FDA) has yet to approve or clear this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The results in this report are intended for the review of the physician caring for this patient and are to be interpreted in the context of clinical findings and other laboratory findings. This document contains private and confidential healthcare information protected by federal and state law. If you receive this report in error, please call: (866) 299-8998. For more information about this test, please visit www.smarthealthdx.com.

Patient Information	Specimen Information	Practitioner Information
Name	Collection Date/Time 05/13/2025 09:40 PT	Name Maximus, Paul
Age 69 Sex F	Received Date/Time 05/15/2025 10:00 PT	Client ID 3047 Paul Maximus
DOB	Report Date/Time 05/27/2025 17:39 PT	Address 903-750W. Broadway
Accession ID	Report Status Final	Vancouver, BC V5Z 1K1

About this Test

The SmartVascular Dx Score quantifies endothelial damage and predicts the likelihood of Acute Coronary Syndrome (ACS-heart attack, unstable angina and sudden cardiac death) within 5 years. The SmartVascular Dx test measures the body's immune response pathway of coronary endothelial damage causing the formation, progression and likelihood of cardiac lesion rupture that can lead to a heart attack.

Protein Result		(Relative % Contribution to the SmartVascular Dx Score)		
SmartVascular Dx Biomarker	Relation To Endothelial Damage & Unstable Cardiac Lesions	Normal	Borderline	Elevated
Measures Immune Formation & Free Radical Damage				
IL-16	Signaling molecule that triggers the repair process; often associated with stress, obesity, and sleep apnea			106.6
Measures Immune Response				
MCP-3	Recruits monocyte/macrophages that form foam cells to clean up damaged cells, lipids, and cellular debris	24.11		
Eotaxin	Recruits eosinophils that consume fibrin and facilitates repair			29.4
CTACK	Recruits T-cells that regulate the local inflammatory response at the site of a lesion	23.53		
Measures Disease Progression				
Fas	Soluble form prevents programmed cell death (apoptosis) - usually indicates healing			58.04
Fas Ligand	Initiates programmed cell death and recycling - associated with more acute processes			31.71
HGF	Governs tissue remodeling & repair			63.42

Test Comments

The SmartVascular Dx measures protein biomarkers of active Unstable Lesion formation and progression produced by the pathways (chemotaxis, apoptosis, cell proliferation, inflammation & angiogenesis). An integrated score calculated with established clinical risk factors demonstrates clinical utility that identifies the vulnerable patient and improves accuracy in cardiovascular risk classification, which could lead to improved preventive care and fewer deaths.

METHODOLOGY: Chemiluminescent Immunoassay

Morningstar Laboratories, a Smart Health Diagnostics Company, is authorized under the Clinical Laboratory Improvement Amendments (CLIA) to develop and perform laboratory testing. This test was developed, and Morningstar Laboratories determined its performance characteristics. The US Food and Drug Administration (FDA) has yet to approve or clear this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The results in this report are intended for the review of the physician caring for this patient and are to be interpreted in the context of clinical findings and other laboratory findings. This document contains private and confidential healthcare information protected by federal and state law. If you receive this report in error, please call: (866) 299-8998. For more information about this test, please visit www.smarthealthdx.com.

Patient Information	Specimen Information	Practitioner Information
Name	Collection Date/Time 05/13/2025 09:40 PT	Name Maximus, Paul
Age 69 Sex F	Received Date/Time 05/15/2025 10:00 PT	Client ID 3047 Paul Maximus
DOB	Report Date/Time 05/27/2025 17:39 PT	Address 903-750W. Broadway
Accession ID	Report Status Final	Vancouver, BC V5Z 1K1


Heart Age

Heart age is designed to give you an understanding of your heart health within a 5-year time frame. Your age has an expected risk score even if everything is normal. When your calculated SmartVascular Dx Score is higher than your expected heart age, that means that your heart age is older than your current age.

Your Age	69
Your Calculated Heart Age	>80
Your Heart Age Difference	>11

How Heart Age is Calculated

5-Year SmartVascular Dx Risk Score



SmartVascular Dx Score Serial Results

No prior results available for serial reporting.

The SmartVascular Dx measures protein biomarkers of active Unstable Lesion formation and progression produced by the pathways (chemotaxis, apoptosis, cell proliferation, inflammation & angiogenesis). An integrated score calculated with established clinical risk factors demonstrates clinical utility that identifies the vulnerable patient and improves accuracy in cardiovascular risk classification, which could lead to improved preventive care and fewer deaths.

METHODOLOGY: Chemiluminescent Immunoassay

Morningstar Laboratories, a Smart Health Diagnostics Company, is authorized under the Clinical Laboratory Improvement Amendments (CLIA) to develop and perform laboratory testing. This test was developed, and Morningstar Laboratories determined its performance characteristics. The US Food and Drug Administration (FDA) has yet to approve or clear this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The results in this report are intended for the review of the physician caring for this patient and are to be interpreted in the context of clinical findings and other laboratory findings. This document contains private and confidential healthcare information protected by federal and state law. If you receive this report in error, please call: (866) 299-8998. For more information about this test, please visit www.smarthealthdx.com.